Gadolinium is not necessary for surveillance MR imaging in children with chiasmatic-hypothalamic low-grade glioma.
gadolinium
hypothalamic-chiasmatic
low-grade glioma
pediatric
surveillance imaging
Journal
Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
revised:
19
05
2021
received:
19
04
2021
accepted:
25
05
2021
pubmed:
17
6
2021
medline:
18
3
2022
entrez:
16
6
2021
Statut:
ppublish
Résumé
Patients with chiasmatic-hypothalamic low-grade glioma (CHLGG) have frequent MRIs with gadolinium-based contrast agents (GBCA) for disease monitoring. Cumulative gadolinium deposition in the brains of children is a potential concern. The purpose of this study is to evaluate whether MRI with GBCA is necessary for determining radiographic tumor progression in children with CHLGG. Children who were treated for progressive CHLGG from 2005 to 2019 at Texas Children's Cancer Center were identified. Pre- and post-contrast MRI sequences were separately reviewed by one neuroradiologist who was blinded to the clinical course. Three dimensional measurements and tumor characteristics were evaluated. Radiographic progression was defined as a 25% increase in size (product of two largest dimensions) compared with baseline or best response after initiation of therapy. A total of 28 patients with progressive CHLGG were identified with a total of 683 MRIs with GBCA reviewed (mean 24 MRIs/patient; range, 11-43 MRIs). Radiographic progression was observed 92 times, 91 (99%) on noncontrast and 90 (98%) on contrast imaging. Sixty-seven progressions necessitating management changes were identified in all (100%) noncontrast sequences and 66 (99%) contrast sequences. Tumor growth > 2 mm in any dimension was identified in 184/187 (98%) noncontrast and 181/187 (97%) with contrast imaging. Metastatic tumors were better visualized on contrast imaging in 4/7 (57%). MRI without GBCA effectively identifies patients with progressive disease. When imaging children with CHLGG, eliminating GBCA should be considered unless monitoring patients with metastatic disease.
Sections du résumé
BACKGROUND
Patients with chiasmatic-hypothalamic low-grade glioma (CHLGG) have frequent MRIs with gadolinium-based contrast agents (GBCA) for disease monitoring. Cumulative gadolinium deposition in the brains of children is a potential concern. The purpose of this study is to evaluate whether MRI with GBCA is necessary for determining radiographic tumor progression in children with CHLGG.
METHODS
Children who were treated for progressive CHLGG from 2005 to 2019 at Texas Children's Cancer Center were identified. Pre- and post-contrast MRI sequences were separately reviewed by one neuroradiologist who was blinded to the clinical course. Three dimensional measurements and tumor characteristics were evaluated. Radiographic progression was defined as a 25% increase in size (product of two largest dimensions) compared with baseline or best response after initiation of therapy.
RESULTS
A total of 28 patients with progressive CHLGG were identified with a total of 683 MRIs with GBCA reviewed (mean 24 MRIs/patient; range, 11-43 MRIs). Radiographic progression was observed 92 times, 91 (99%) on noncontrast and 90 (98%) on contrast imaging. Sixty-seven progressions necessitating management changes were identified in all (100%) noncontrast sequences and 66 (99%) contrast sequences. Tumor growth > 2 mm in any dimension was identified in 184/187 (98%) noncontrast and 181/187 (97%) with contrast imaging. Metastatic tumors were better visualized on contrast imaging in 4/7 (57%).
CONCLUSION
MRI without GBCA effectively identifies patients with progressive disease. When imaging children with CHLGG, eliminating GBCA should be considered unless monitoring patients with metastatic disease.
Substances chimiques
Contrast Media
0
Gadolinium
AU0V1LM3JT
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
e29178Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
Gulani V, Calamante F, Shellock FG, Kanal E, Reeder SB. Gadolinium deposition in the brain: summary of evidence and recommendations. Lancet Neurol. 2017;16(7):564-570.
Levine D, Mcdonald RJ, Kressel HY. Gadolinium retention after contrast-enhanced MRI. JAMA. 2018;320(18):1853-1854.
Pinter NK, Klein JP, Mechtler LL. Potential safety issues related to the use of gadolinium-based contrast agents. Continuum. 2016;22(5):1678-1684.
Flood TF, Stence NV, Maloney JA, Mirsky DM. Pediatric brain: repeated exposure to linear gadolinium-based contrast material is associated with increased signal intensity at unenhanced T1-weighted MR imaging. Radiology. 2017;282(1):222-228.
Young JR, Orosz I, Franke MA, et al. Gadolinium deposition in the paediatric brain: T1-weighted hyperintensity within the dentate nucleus following repeated gadolinium-based contrast agent administration. Clin Radiol. 2018;73(3):290-295.
Semelka RC, Commander CW, Jay M, Burke LMB, Ramalho M. Presumed gadolinium toxicity in subjects with normal renal function: a report of 4 cases. Invest Radiol. 2016;51(10):661-665.
Ramalho J, Semelka RC, Ramalho M, Nunes RH, Alobaidy M, Castillo M. Gadolinium-based contrast agent accumulation and toxicity: an update. AJNR Am J Neuroradiol. 2016;37(7):1192-1198.
Packer RJ, Pfister S, Bouffet E, et al. Pediatric low-grade gliomas: implications of the biologic era. Neuro-oncology. 2017;19(6):750-761.
Banerjee A, Jakacki RI, Onar-Thomas A, et al. A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study. Neuro-oncology. 2017;19(8):1135-1144.
Gururangan S, Fangusaro J, Poussaint TY, et al. Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas-a Pediatric Brain Tumor Consortium study. Neuro-oncology. 2014;16(2):310-317.
Saitta L, Heese O, Förster A-F, et al. Signal intensity in T2' magnetic resonance imaging is related to brain glioma grade. Eur Radiol. 2011;21(5):1068-1076.
Ellingson BM, Lai A, Nguyen HN, Nghiemphu PL, Pope WB, Cloughesy TF. Quantification of nonenhancing tumor burden in gliomas using effective T2 maps derived from dual-echo turbo spin-echo MRI. Clin Cancer Res. 2015;21(19):4373-4383.
Blom G. Statistical estimates and transformed beta-variables. New York, Almquist und Wiksell, Stockholm: Wiley; 1958.
Bland JM, Altman DG. Calculating correlation coefficients with repeated observations: part 1-Correlation within subjects. BMJ. 1995;310(6977):446.
Obuchowski NA. Nonparametric analysis of clustered ROC curve data. Biometrics. 1997;53(2):567-578.
Safari S, Baratloo A, Elfil M, Negida A. Evidence based emergency medicine; part 5 Receiver operating curve and area under the curve. Emerg (Tehran). 2016;4(2):111-113.
Fleiss JL LB, Paik MC. Statistical methods for rates and proportions. 3rd ed. John Wiley; 2013.
Hill BJ, Gadde JA, Palasis S. Subependymal giant cell astrocytoma size measurement in tuberous sclerosis complex: noncontrast vs contrast-enhanced 3-dimensional T1-weighted magnetic resonance imaging (MRI). J Child Neurol. 2019;34(14):922-927.
Gaillard A-L, Crombé A, Jecko V, et al. Magnetic resonance imaging diagnosis of subependymal giant cell astrocytomas in follow-up of children with tuberous sclerosis complex: should we always use contrast enhancement?. Pediatr Radiol. 2020;50(10):1397-1408.
He JQ, Iv M, Li G, Zhang M, Hayden Gephart M, Noncontrast T2-weighted magnetic resonance imaging sequences for long-term monitoring of asymptomatic convexity meningiomas. World Neurosurg. 2020;135:e100-e105.
Bonneville J-F. Long-term MRI surveillance of pituitary macroadenomas: gadolinium is not obligatory. Pituitary. 2019;22(1):100-102.
Maloney E, Stanescu AL, Perez FA, et al. Surveillance magnetic resonance imaging for isolated optic pathway gliomas: is gadolinium necessary?. Pediatr Radiol. 2018;48(10):1472-1484.
Marsault P, Ducassou S, Menut F, Bessou P, Havez-Enjolras M, Chateil J-F. Diagnostic performance of an unenhanced MRI exam for tumor follow-up of the optic pathway gliomas in children. Neuroradiology. 2019;61(6):711-720.
Fangusaro J, Witt O, Hernáiz Driever P, et al. Response assessment in paediatric low-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. Lancet Oncol. 2020;21(6):e305-e316.
Hukin J, Siffert J, Velasquez L, Zagzag D, Allen J. Leptomeningeal dissemination in children with progressive low-grade neuroepithelial tumors. Neuro-oncology. 2002;4(4):253-260.
Perilongo G, Garrè ML, Giangaspero F. Low-grade gliomas and leptomeningeal dissemination: a poorly understood phenomenon. Child's Nervous System. 2003;19(4):197-203.
Radbruch A, Richter H, Fingerhut S, et al. Gadolinium deposition in the brain in a large animal model: comparison of linear and macrocyclic gadolinium-based contrast agents. Invest Radiol. 2019;54(9):531-536.
Rowe SK, Rodriguez D, Cohen E, et al. Switching from linear to macrocyclic gadolinium-based contrast agents halts the relative T(1)-weighted signal increase in deep gray matter of children with brain tumors: a retrospective study. J Magn Reson Imaging. 2020;51(1):288-295.